Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-sponsored phase 1/2 clinical trial of AVR-RD-05 for Hunter syndrome

Trial Profile

An investigator-sponsored phase 1/2 clinical trial of AVR-RD-05 for Hunter syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVR-RD 05 (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 11 May 2023 Status changed from not yet recruiting to recruiting, according to an AVROBIO media release.
    • 23 Mar 2023 According to an AVROBIO media release, collaborators at UoM highlighted data validating their manufacturing process in preparation for this study which is anticipated to start later in 2023.
    • 14 Sep 2022 According to an AVROBIO media release, UoM expects to dose the first patient in the trial in 1H 2023, the study will be overseen by Brian Bigger, Ph.D.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top